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Abstract
Background: One of the signatures of Alzheimer's disease is the accumulation of aggregated
amyloid protein, A, in the brain. A arises from cleavage of the Amyloid Precursor protein by 
and  secretases, which present attractive candidates for therapeutic targeting. Two -secretase
candidates, ASP-1 and ASP-2, were identified as aspartic proteases, both of which cleave the
amyloid precursor at the -site. These are produced as immature transmembrane proteins
containing a pro-segment.
Results: ASP-2 expressed in HEK293-cells cleaved the Swedish mutant amyloid precursor at
different -sites at different pHs in vitro. Recent reports show that furin cleaves the pro-peptide of
ASP-2, whereas ASP-1 undergoes auto-catalysis. We show that purified recombinant ASP-2 cleaves
its own pro-peptide at ph 5 but not pH  8.5 as seen by mass spectrometry, electrophoresis and N-
terminal sequencing.
Conclusion: We suggest that ASP-2 processing as well as activity are influenced by pH, and hence
the cellular localisation of the protein may have profound effects on the production of A. These
factors should be taken into consideration in the design of potential inhibitors for these enzymes.
Background
Alzheimer's disease is a common age-related dementia
which is characterised pathologically by the appearance of
brain senile plaques [1,2] composed primarily of aggre-
gated forms of A. These are 39–43 residue peptides re-
leased following proteolytic processing of the
transmembrane precursor glycoprotein, APP. The amy-
loidogenic pathway requires the APP to be sequentially
cleaved by  and  secretases [3,4]. -Secretase cleaves APP
close to the membrane to produce APPs (secreted), and
the 12-kDa, C100 transmembrane stub, subsequently
cleaved by -secretase to produce the A peptide and a cy-
toplasmic fragment with very short half life. -Secretase
cleaves APP within the A sequence thus preventing its
formation producing the N-terminal APPs domain and
the 10-kDa membrane-localised C-terminal stub, C83. As
aggregated A is thought to promote neuronal death [5–
7], the secretases represent potential drug targets for the
treatment and/or prevention of AD. Presenilin-1 was sug-
gested to be the ideal candidate for -secretase [8] whereas
-secretase has been characterised as ADAM10 disintegrin
and metalloprotease [9]. Recently, several groups used ex-
pression cloning, genomic search, or purification and pro-
teomic analysis [10–13] to clone and identify -secretase
as an aspartic endopeptidase (EC 3.4.23) named BACE (-
site APP clevage enzyme), ASP-2 (aspartic protease 2), or
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memapsin 1. An additional candidate, ASP-1, BACE-2 or
memapsin-2, has also been cloned [14–16]. The ASP-2
gene codes for a signal peptide, a pro-peptide (22-TQH-
GIRLPLRSGLGGAPLGLRLPR-46), followed by the catalyt-
ic domain, a transmembrane segment and a cytoplasmic
C-terminal tail. Several cysteine residues are present, six of
which are in the lumenal domain which may form in-
tramolecular disulphide bridges contributing to the fold-
ing of the active site [17]. Both ASP-1 and -2 are
extensively glycosylated [18] and phosphorylated [19],
and contain S-palmitoyl groups which may aid mem-
brane anchorage[20].
Nearly all aspartic proteinases (EC 3.4.23.X) are synthe-
sized as zymogens which are converted to active enzymes
at acidic pH by proteolytic cleavage of the pro-segment
[21,22]. This process is autocatalytic for some pro-en-
zymes such as pepsinogen [23–25] and cathepsins D [26]
and E [27]. Furin is thought to cleave the ASP-2 pro-do-
main [20,28,29], though other pro-protein convertases
were effective as well [20,30]. In contrast, ASP-1 has been
demonstrated to cleave its own pro-peptide [31]. Al-
though the pro-sequences of ASP-1 and ASP-2 are dissim-
ilar we investigated whether ASP-2 also cleaves its pro-
peptide. The activity of ASP-2 was assessed using the
Swedish mutant form of APP [32] which is more readily
cleaved by -secretase than the wild type [33]. We investi-
gated the effects of pH on ASP-2 processing and activity.
We report that pH affects the pro-domain removal of ASP-
2 in vitro as well as its site of -secretase cleavage in APP to
produce A.
Results
Expression and Ni2+-affinity purification of recombinant 
ASP-1 and ASP-2 in HEK293 cells
HEK293 cells were transfected with the -secretase candi-
dates ASP-1 or ASP-2 pcDNA3.1mycHis clones and select-
ed for stable transfection with Geneticin (800 g/ml).
HEK293 cell lines have been used by others to overexpress
these enzymes [34,35] and have also been used to study
the effects of -secretase cleavage on recombinant APP
[33,36]. Cell lysates from positive clones were analysed by
SDS-PAGE and western blotting with an anti-myc anti-
body to detect the recombinant ASP-1 and ASP-2 proteins.
The myc epitope is encoded in frame downstream of the C-
terminal of the proteins followed by a 6-Histidine tag for
affinity purification. Both recombinant ASP-1 and ASP-2
were expressed and detected by western blotting as 55–70-
k and 65–80-k bands, respectively, higher than the esti-
mated molecular weights of the pro-apoproteins (53.4
and 53.7-kDa including the pro-peptide domains), main-
ly due to glycosylation as predicted by their amino acid se-
quences and shown in recent reports by Charlwood et al.,
2001. Recombinant ASP-2 was purified by Ni2+-affinity
chromatography. Silver-stained SDS-PAGE confirmed the
purity of ASP-2 from other contaminants as seen in figure
1A; lower bands (dotted arrows) seen in the purified prep-
aration are due to artefactual materials also present in the
negative control sample (note the presence of higher mo-
lecular weight forms of ASP-2). Immunoblotting of the
same preparation of ASP-2 detected with the anti-myc an-
tibody, (figure 1, 1B) confirms purification of ASP-2. The
most prevalent of these ASP-2 proteins was a 75-k band.
We used an affinity-purified antibody raised against the C-
terminal peptide of ASP-2 (anti-ASP-2) to characterise the
recombinant proteins. This antibody was specific for ASP-
2 and did not cross-react with ASP-1 or other cellular pro-
teins as characterised by ELISA and western blotting.
Removal of N-linked oligosacharides increased the rela-
tive mobility of ASP-2 from 65–80-k to 50–60-k, a size re-
sembling the estimated molecular weights of the core
protein confirming glycosylation as reported by others ei-
ther by suppression of N-glycosylation or deglycosylation
[18,34]. When increased amounts of protein were loaded
(as in figure 2, 2A) the anti-ASP-2 IgG detected ASP-2
bands of higher Mw, larger than 200-k or at Mr~140-k,
shown with triple and double arrows, respectively; the
140 k band was also visible by silver staining as indicated
by the double arrow in figure 1A. These correspond in size
to three or two ASP-2 molecules, respectively, implying
ASP-2 oligomerisation into a trimer and dimer. The sensi-
tivity of the putative dimer (140-k) to PNGase resulted in
a reduction of size by ~30-k, to yield a band migrating as
100-k, equivalent to the behaviour of 2 linked monomers.
Reduction with DTT and -mercaptoethanol (figure 2, 2B)
almost completely removed the ~200-k protein and in-
creased the intensity of the 75-k band, but failed to affect
the appearance of the putative dimer (140-k) suggesting
strong intramolecular interactions. The oligomers were
visible in freshly produced and purified ASP-2, though the
200-k protein was more prominent (data not shown)
upon longer storage and at higher protein concentrations
indicating that this was partly due to non-specific aggrega-
tion. An additional observation was the delayed mobility
of ASP-2 in reducing conditions (figure 2, 2B) which is
possibly due to loss of globular structure during reduction
of intramolecular disulphide links described previously
by Haniu et al., 2000.
ASP-2 undergoes a two-step pro-peptide cleavage at acidic 
pH
We investigated the processing of ASP-2 at different pH
values, since self-activation of other aspartic proteases
such as pepsinogen [23] has been shown to be sensitive to
pH. Pure ASP-2 was dialysed into a buffer of ph 5 or pH
8.5, immediately following purification. Incubation of
the protein at room temperature was carried out prior to
PAGE analysis. A sample before dialysis was also analysed
alongside the ASP-2 at pH 8.5 and ph 5. A western blotBMC Biochemistry 2002, 3 http://www.biomedcentral.com/1471-2091/3/25
Page 3 of 12
(page number not for citation purposes)
analysis of these samples, depicted in figure 3, 3A, reveals
a small shift in molecular weight of 3 k for the monomeric
band and ~8 k for the dimer at ph 5. This was the first in-
dication that cleavage of the pro-peptide (2.56 k) was oc-
curring, which was also mirrored, by increased mobility in
the putative dimer. PNGase treatment of the ph 5 and pH
8.5 ASP-2 samples revealed the deglycosylated proteins to
be resolved in 3 and 2 bands (figure 3, 3B), respectively.
The bands of the ph 5 sample were smaller (~3-k) than the
ASP-2 bands in the pH 8.5 sample. The fact that PNGase
did not reduce the ASP-2 protein to a single band of the
unmodified protein is probably due to other modifica-
tions mentioned earlier, such as palmitoylation [20] and
phosphorylation [18,19]. The triplet at ph 5 is consistent
with deglycosylated proteins with the pro-segments re-
moved (processed), with and without additional modifi-
cations. The highest band is possibly non-processed
deglycosylated protein, because its intensity decreases
upon incubation at 37C.
Pure ASP-2 that had been incubated at ph 5 after adjust-
ment of the pH with acetic acid was analysed by mass
spectrometry to further detect the cleaved pro-peptide
(figure 4). The sample dialysed at ph 5 could not be used
since the small, cleaved fragments would have been dia-
lysed out of the 4 k-exclusion membrane. Compared to
pH 8.5 (profile B), the sample at ph 5 (profile A) displays
two distinct peaks of size 1094 and 1352 Da. The peak at
1094 corresponds closely to the estimated m/z of the N-
terminal fragment of the pro-sequence namely, QHGIRL-
PLR (1089Da) (the N-terminal fragment from the Pro-se-
quence from which the N-terminal T had been removed-
as found by N-terminal sequencing-see below, P1) and
the peak at 1352 corresponds to a dehydrated form (-18
mass) of the penultimate N-terminal fragment of the Pro-
sequence, P2 SGLGGAPLGLRLPR (1364 Da) respectively.
The mass spectra indicated firstly that pro-peptide cleav-
age occurs readily at ph 5 at two sites within the pro-do-
main. N-terminal sequencing of these protein
preparations revealed the presence of two sequences in
the pH 8.5 preparation, namely ETDEEPEE (mature pro-
tein starting at E46), and QHGIRL (immature protein
with an intact pro-domain starting at Q23). The presence
of protein without its pro-domain, within the pH 8.5 sam-
ple, is not surprising as this protein was purified from the
cells which themselves are expected to process nascent
ASP-2. In contrast, Edman degradation of the preparation
at pH 5 gave the sequence ETDEEPEE, predominantly ma-
tured protein, which was produced by processing in vitro
following purification and dialysis -at low pH, suggesting
that pro-peptide cleavage of ASP-2 can occur at two sites
by autocatalysis at ph 5 in vitro. To further ascertain auto-
catalytic cleavage we added EDTA to inhibit endogenous
cleavage by furin-like proteases as well as the BACE inhib-
itor (H-Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-Sta-Val-Ala-
Glu-Phe-OH, Bachem, UK) to the incubations at ph 5.
Mass spectrometric analysis of those samples (figure 5)
showed that EDTA had no effect on the pro-peptide cleav-
age of ASP-2 as the previously identified peaks of 1094
and 1352 Da are still present in this sample as they are in
Figure 1
Ni2+-affinity purification of ASP-2. A detergent extract
was prepared from a total of 50  106ASP-2-transfected cells
as described in the methods, in the presence of protease
inhibitors and loaded on an equilibrated Ni2+-charged agar-
ose column, following dilution of the lysate to 0.5% (wt/vol)
detergent and pure protein was eluted in fractions of 1 ml
with 300 mM imidazole solution with 0.1% detergent. Eluates
were loaded on a SDS-PAGE and proteins were detected by
silver staining, (panel A) and anti-myc antibody developed by
ECL (Panel B). Molecular weight standards are indicated in
the first lane whereas the last lane shows a sample of elution
buffer in loading buffer without protein. Typically, 20% yield
was recovered following purification, amounting to approxi-
mately 40–60 g of protein for a preparation from 50  106
cells. Solid arrows indicate the positions of the ASP-2 pro-
tein; the double solid arrow designates a pitative ASP-2
dimer.
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the control which did not contain any inhibitor. Most im-
portantly incubation of ASP-2 with the BACE inhibitor re-
sulted in the disappearance of these peaks suggesting that
pro-peptide cleavage is a result of autocatalysis.
Diverse cleavage of APPswe by ASP-2 at pH 5 and pH 8.5
The activity of recombinant ASP-2 was assessed using the
Swedish mutation APP (APPswe) purified using the anti-
CT15 IgG from stably transfected HEK293 cells. Initially
[35S]-labelled C-terminal APPswe polypeptides were iso-
lated by immunoprecipitation with anti-CT15 IgG and
protein-A-agarose and resuspended in reaction buffer (pH
8.5) prior to the addition of ASP-2. Figure 6, 6A, depicts
an autoradiogram of a 16.5% Tris-Tricine gel where
APPswe was incubated with or without ASP-2. In the ab-
sence of ASP-2 we noted the presence of a small band of
~9.25 ( 0.6, n = 3)-k corresponding to the C-83 APPswe
fragment produced by endogenous -secretase cleavage.
The addition of ASP-2 resulted in an additional band at
~12.4-k consistent with the estimated size of the C-termi-
Figure 2
ASP-2 post-translational modifications; glycosylation and disulphide linkagesPanel A: ASP-2 samples were dena-
tured by boiling in the presence of SDS and prior to treatment with PNGase, according to the manufacturer's protocol. Glyc-
osylated and deglycosylated samples are depicted. A reduction in size of ~15-k is seen in the presence of PNGase due to the
removal of N-linked sugars. Note the presence of higher ASP-2 bands, indicated with double arrows, which are similarly, degly-
cosylated. Panel B: ASP-2 samples were denatured in the presence or absence of a mixture of 10 mM DTT and 2% (vol/vol)
-mercaptoethanol designated as reducing agent. A reduction in the amount of the largest ASP-2 protein (marked with 3
arrows) is noted in the presence of reducing agent as well as a reduction in the mobility of ASP-2 proteins. Ni2+-affinity purified
ASP-2 was used at a concentration of 40 nM. Western blots were detected with anti-ASP-2. Bold arrows designate larger puta-
tive, dimer and multimer.
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nal stub after cleavage of -secretase at the A (1–40/42)
site. To confirm the identity of this band the same reac-
tions were carried out with non-radiolabelled substrate
and the proteolytic fragments were detected by western
blotting using either the anti-CT15 antibody (figure 6, 6B
top panels) or the 6E10 (figure 6, 6B bottom panels) an-
tibody, specific for the N-terminal of A. These reactions
were carried out both at optimum pH for aspartic protease
activity, pH 5, as well as at pH 8.5 for comparison and the
whole sample was analysed. ASP-2 was also pre-incubated
at the respective pH. The arrows indicate the -secretase
cleaved fraction to be present in both pH 8.5 and ph 5.
Two fragments (12.39 ( 0.24, n = 3) and 10.43 ( 0.45,
n = 3)-k, designated 1-C100 and 2-C90, respectively)
appear from ASP-2 cleavage at ph 5, consistent with frag-
ments occurring by -secretase cleavage at the A (1–40/
42)-producing 1 site starting with D1, and the E11, 2-
site resulting in A (11–40/42). Incubation of the purified
recombinant ASP-2 with the APPswe at ph 8.5 also pro-
duced cleavage at the 1-site as only the 12.39 k band is
visible. The 12.4-k band was also labelled by the 6E10 an-
tibody further confirming that it is the result of APPswe
cleavage at the 1-site. These results reveal that the activity
of ASP-2 is influenced by pH which apparently governs
the site at which ASP-2 cleaves the APPswe protein.
Figure 3
Reduction in size of ASP-2 upon incubation at acidic pH proposes autocatalytic pro-peptide cleavagePanel A:
Pure ASP-2 samples were dialysed at ph 5 and pH 8.5 immediately following purification and subsequently incubated for 2 hrs
at room temperature as described in the methods. The initial non-dialysed sample was also incubated before all the samples
were all analysed by SDS-PAGE and western blotting. A reduction of the size of ASP-2, ph 5 was observed compared to the ini-
tial eluate and the pH 8.5 samples. Note the presence of higher Mw bands ~140-k which also displayed increased mobility at ph
5. Panel B: The same ASP-2 samples dialysed at different pH were treated with PNGase for better resolution of the protein
bands. The samples dialysed at pH 5 were either not incubated (first two lanes) or pre-incubated before PNGAse treatment.
These samples needed to be titrated to pH 8.5 before deglycosylation. Similarly samples at pH 8.5 were treated or not with
PNGase as indicated on the figure. Compared to the respective sample at pH 8.5, the ph 5 deglycosylated ASP-2 reveals the
lowest ASP-2 band visible on this blot at ~50-k, possibly mature protein without the pro-peptide and sugars, suggesting matu-
ration of ASP-2. Pre-incubation of the sample at 37C increased the intensity of this band compared to the samples that were
not pre-incubated implying that its appearance is time-dependent on incubation of the protein at a certain pH. For both panels
sizes of molecular weight standard proteins are indicated on the left. Both panels were probed with anti-ASP-2 IgG and devel-
oped with ECL.
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Discussion
Understanding what governs the activity of ASP-2 toward
the APP substrate at a cellular and molecular level could
facilitate the discovery of compounds that could inhibit
the development of AD. It was therefore important to
study the maturation, processing and activity of ASP-2
and relate that to the proteolytic events that lead to A
production. In agreement with several other reports
[15,17,18,37] glycosylated proteins were successfully pro-
duced in HEK293 cells displaying mobility of ~55–70 and
65–80-k, for ASP-1 and ASP-2, respectively. The broad-
ness of these bands suggested a heterogeneous protein
population, as a result of variable translational modifica-
tion which was mainly due to glycosylation and possibly
pro-processing and as also detected by others in the fully
glycosylated, endoglycosidase H-resistant ASP-2 forms
[17,18,31,34]. Using a new anti-ASP-2 IgG, we detected
the presence of higher molecular weight proteins in the
purified preparations, by analysis under denaturing SDS-
PAGE, which corresponded in size to ASP-2 homo-mul-
timers. Oligomerisation has also been identified [38] for
pepsin [39]and cathepsin E [27,40]. A putative dimer was
clearly noted at ~150-k, corresponding to (ASP-2)2, which
was also sensitive to deglycosylation giving rise to a
Figure 4
Mass spectrometry of ASP-2 samples at ph 5 and 8.5 Pure ASP-2 samples that were prepared as described were
titrated to pH 5 and pH 8.5 and incubated at room temperature. The first panel shows a profile following incubation at pH 8.5
and the second panel, at pH 5. The pro-peptide has an estimated Mw = 2535-Da. the ph 5 contains two peaks of 1094.4 and
1352.3 that are not present at pH 8.5. These correspond closely to the estimated mw of two fragments of the pro-sequence
namely, QHGIRLPLR (1089) and SGLGGAPLGLRLPR (1364). Solid lines display the detected peaks in each sample. Dotted
lines indicate the estimated positions corresponding to the pro-peptide fragments as calculated above; these estimated values
of these peaks are boxed. The profiles seen indicate percentage of intensity against mass/charge ratio.
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change in mobility which corresponded to two mono-
mers. The appearance of the largest ASP-2 forms was part-
ly dependent on concentration and length of storage
suggesting this is partly due to non-specific aggregation. In
contrast, the putative dimers (~140 kDa) were evident
even in fresh samples and were mainly insensitive to re-
ducing agent providing evidence for the existence of
strong non-disulphide protein-protein interactions not
broken by high salt and non-ionic detergents used during
purification or the strong denaturing conditions of SDS-
boiling used during SDS-PAGE. Recently a laboratory in
Germany reported the isolation of native active ASP-2
dimers from human brain homogenates, (Multhaup, G.
and colleagues from Germany, unpublished data[41]).
These native dimers were similar to those observed in our
preparations as they were SDS-resistant.
Activation of acidic proteases by removal of a pro-peptide
occurs either by autocatalysis as in the case of pepsinogen
[23,25] and other aspartic proteases, or the action of other
proteases, like Cathepsins S and L which activate Cathep-
sin C [38]. Several reports by other laboratories, showed
furin to successfully cleave the ASP-2 pro-segment [20,29]
also demonstrating that recombinant ASP-2 does not
cleave its own synthetic or recombinant fusion pro-seg-
ments. However, Hussain et al. (2001), have recently
shown that minimal cleavage of ASP-1 pro-domain is
achieved by ASP-2 whereas ASP-1 displayed a unimolecu-
Figure 5
BACE inhibitor reduces pro-peptide cleavage of ASP-2 at pH 5 Pro-peptide cleavage of ASP-2 results in two peaks of
1094.4 and 1352.3 not present in the sample incubated with the BACE inhibitor (Mw = 1651 g/mol). These peaks are present
when ASP-2 was incubated with EDTA. Samples of pure ASP-2 were prepared as described. Titration to ph 5 was carried out
at 4C and immediately EDTA (5 mM) or BACE inhibitor (20 M, according to the protocol in Hussain et al. 2001) were
added. Control ASP-2 at ph 5 contained no inhibitor. The peak of 1750 seen in the BACE inhibitor sample is also present in the
inhibitor profile (not shown) and in agreement with its molecular weight is the inhibitor itself; additional larger bands are also
present the inhibitor control sample. Following incubation samples were analysed by mass spectrometry as described in the
methods.
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lar pro-peptide auto-removal. Here we demonstrated in
vitro cleavage of the ASP-2 pro-peptide in full-length, pure,
recombinant proteins instigated by incubation of ASP-2 at
acidic pH, implying autocatalysis. We propose that cleav-
age occurs at two sites RLPLRS32 and RLPRE46 within
the pro-domain, suggesting a two-step cleavage resem-
bling the mechanism of maturation of other aspartic pro-
teinases by autocatalysis (for a review see Richter et al.,
1998). We have not investigated to see if the pro-sequence
removal from ASP-2 is a unimolecular reaction, or due to
the attack of a second ASP-2 molecule. APP cleavage at
both the Asp1 (1-site) as well as the Glu11 (2-site) po-
sitions shows that ASP-2 has a preference to cleave N-ter-
minally to an acidic residue as is the case for the pro-
Figure 6
In vitro cleavage of APPswe by pure recombinant ASP-2; differential cleavage occurs at acidic or alkaline
pHPanel A: anti-CT15 IgG immunoprecipitated (35S)-labelled APPswe (2 M APPswe) was incubated with either just buffer
(lane 1) or with pure ASP-2 at 6 nM (lane 2). The total reaction was analysed on a16.5% Tris-Tricine gel, stained and fixed, and
amplified as described in the methods. The gel was then dried and exposed on a Kodak-X-Omat film. Panel B: Immunoprecip-
itated APPswe samples as above were incubated with or without ASP-2 as described above at pH 5 or ph 8.5 as indicated in
the figure. The blots were developed with anti-CT15 IgG that is specific for the C-terminal of APP. The bottom panels are the
same reaction probed with the 6E10 clone antibody, which was raised specifically against the first residues of A and thus only
recognises -secretase cleaved fragments that produce A. Panel C: A typical gel calibration standard curve for the low
molecular weight standards (carbonic anhydrase, 34.3 kDa, soybean trypsin inhibitor, 26 kDa, Lysozyme, 17.9, kDa, Aprotinin,
8 kDa, insulin, 4 kDa) plotted as the Log10 of molecular weight against Rf, for size estimation of peptides. For all panels - and
-secretase cleavage are designated by arrows and the letters  or  for the respective secretase cleavage. 1 and 2 indicate
cleavage at the Aspartate (1) and the Glutamate (11) sites of A, producing the C-100 and a C-90 fragment respectively.
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Mw (kDa) 1 2
34.3
26
17.9
8
0.75
1.25
1.75
1 1.2 1.4 1.6 1.8
Rf
L
o
g
M
w
A
β2 α α
β1 β1
B pH5 pH8.5
a
n
t
i
-
C
T
1
5
ASP-2 - +
ASP-2 -+ -+
L
a
b
e
l
l
e
d
w
i
t
h
[
5
3
S
]
-
M
e
t
β
α
6
E
1
0
β1 β1
IgG
ASP-2 -+ -+
[53S]-APPswe
C
IgGBMC Biochemistry 2002, 3 http://www.biomedcentral.com/1471-2091/3/25
Page 9 of 12
(page number not for citation purposes)
peptide cleavage. However, although the RXXR found in
the ASP-2 pro-sequence is thought to be a minimal se-
quence required for a pro-peptide convertase [43] furin
prefers to cleave C-terminal to two adjacent basic residues.
Recent results [30] showed that ASP-2 processing takes
place in furin-deficient cell lines and suggested that other
pro-peptide convertases are involved whereas Bennett et
al., 2000 observed that a proportion of recombinant ASP-
2 is processed in cells untransfected with furin. Further to
those findings we suggest that ASP-2 can remove its pro-
domain by autocatalysis in vitro, as the BACE inhibitor in-
hibits this process whereas EDTA does not, so that an ad-
ditional pro-peptide convertase may not be required.
Hence, it is possible that autocatalysis could be preferred
under conditions of acidic pH, or in cells or cellular sub-
compartments where pro-peptide convertases are not ex-
pressed. Although other reports have shown that ASP-2
does not cleave its pro-domain in vitro[20,31] the differ-
ence between those and our observations could be due to
differences in the protein preparations. We used full-
length pure proteins for enzyme and substrate whereas,
synthetic peptides as well as truncated fusion proteins
were employed in those studies. These factors in addition
to differences in expression systems (and modifications)
could influence the results observed herein as encoun-
tered for pepsinogen, which displays different activation
kinetics as a fusion than as a whole protein [23]. To con-
clude we suggest that ASP-2 may cleave its pro-peptide in
a two-step mechanism in the absence of any other pro-
tease. Multiple-step removal of pro-sequences has been
seen with other aspartic proteinases, where complete acti-
vation sometimes requires cleavage at more than one site
[42].
We showed in vitro -secretase activity of ASP-2, produc-
ing a C-terminal APP fragment, Mw 12-kDa, consistent
with APPswe cleavage at the 1-site. This cleavage occurs
efficiently at ph 8.5 although the optimum pH of ASP-2
activity is acidic. We must mention though that a propor-
tion of ASP-2 in the ph 8.5 preparation is processed (as
purified from the cells) and could contribute to the -
cleavage of APP we observe at ph 8.5. Cleavage of APPswe
at ph 5, however was different to pH 8.5 as it resulted in
two C-terminal APP fragments each corresponding to
cleavage at the A-producing site (1), and the 2-site de-
scribed by Creemers et al. (2000), to be the most favoura-
ble producing N-terminally truncated, highly cytotoxic
[44], A peptides (11–42) found in patients with the
Flemish mutation. Creemers et al. (2000) suggested that
cleavage at these sites is governed by the expression levels
of ASP-2, in vivo, rather than its maturation. In addition to
that we report here that our results show that pH can also
determine the site of APPswe -cleavage by ASP-2. Results
from our laboratory [45] have localised -cleavage of APP
in the TGN and early endosomes, and recently Huse et al.
(2000) showed TGN localisation for ASP-2 indicating that
these compartments are loci for 2-site cleavage of APP as
their pH is acidic. On the other hand, localisation in the
endoplasmic reticulum and early Golgi imply processing
at neutral to alkaline pH that according to our results gives
cleavage at the 1-site and production of A (1–40/42).
Conclusions
Taken together, our results of ASP-2 pro-peptide process-
ing and diverse APP proteolysis, both happening at ph 5,
imply an additional mode of cellular control of APP -
cleavage whereby subcellular localisation of APP and ASP-
2 in different compartments where the pH is either acidic
or alkaline influences the proteolytic processing of both
ASP-2 as well as of APP by ASP-2 itself and consequently
the production of A. Thus APP cleavage at ph 5 is rele-
vant to Alzheimer's in patients with the Flemish and
Dutch mutations who demonstrate increased deposition
of N-terminally truncated A, resulting from APP process-
ing at the 2-site.
Methods
Materials
Culture media and antibiotics were from Life Technolo-
gies, Paisley, UK. All culture plasticware, were from Nalge
Nunc International, Loughborough, UK. Amino Acids for
peptide synthesis were from Nova Biochem, Nottingham,
UK. Freunds Adjuvant, standard chemicals, 9E10 clone as-
cites fluid (anti-myc), Triton X-100, Nonidet P40, and Ko-
dak X-Omat film were purchased from Sigma-Aldrich
Company Ltd, Dorset, UK, 6E10 (anti-A) from ID labs,
P.O. Box 3556, Glasgow, Scotland, United Kingdom. C-
18 ZIP tips, Centricon-30 concentrators, PVDF membrane
were purchased from Millipore. Automated N-terminal
peptide sequencing was carried out by AltaBiocscience,
University of Birmingham, Edgbaston, UK. All secondary
horseradish peroxidase-linked anti-species IgG, Enhanced
chemiluminescence reagents, ECL Hyper film, Superdex
200HR, Sephadex G-10, were from Amersham Pharmacia
Biotech, UK Ltd, Buckinghamshire, UK, whereas the Ni2+-
affinity resin NiNTA was from Novagen, Nottingham, UK.
Pfx2 Lipids were initially purchased from Invitrogen Life
Technologies, Paisley, UK. Ready-made Tris-Tricine gels
and low molecular weight Kaleidoscope Polypeptide
Standards were from BIORAD, Hemel Hempstead, UK.
Prestained protein molecular weight markers and Acryla-
mide mixture (30% acrylamide: 0.8% (wt/vol) bisacryla-
mide) from National Diagnostics, East Riding of
Yorkshire, UK. Protease Inhibitors and N-glycosidase-F
were purchased from Roche Molecular Biochemicals, East
Sussex, UK.
cDNA constructs and transfections
pCEP4APP695 Hygromycin resistant, APPswe Neomycin
resistant. pcDNA3.1MycHis (A) ASP-1 and 2 were kindlyBMC Biochemistry 2002, 3 http://www.biomedcentral.com/1471-2091/3/25
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donated by the GlaxoSmithKline laboratories, Harlow,
UK. The clones were engineered in frame with the Histi-
dine tag and the Myc epitope, which in that order are
downstream of the coding sequence of the Aspartic pro-
teases (ASP).
Cell manipulations, expression protein purification
For the production of stable colonies HEK293 cells were
transfected using pFX2 lipids as described by the manufac-
turers for 2.5  104 cells per transfection reaction. Positive
transfectants were identified and selected using Geneticin.
Colonies were screened by SDS-PAGE and Western Blot-
ting analysis of cell lysates prepared by direct suspension
of the cells in SDS, 0.1% (wt/vol) followed by sonication
and suspension in gel loading buffer. HEK293 cells were
cultured and propagated as described in Frears et al., 1999.
Cell lysates for affinity- or immuno-purification were pre-
pared by lysis of the cells with frequent agitation for 2 hrs
at 4C in phosphate buffered saline (PBS: 150 mM NaCl
2.7 mM KCl, 10 mM Na2HPO4 and 1.75 mM KH2PO4, at
pH7) supplemented with protease inhibitors, 0.5 mM
EDTA, 1 M Leupeptin, 1 M Pepstatin and 1 mM PMSF,
and Triton X-100, 1% (wt/vol) and NP40, 1% (wt/vol).
For affinity purification of ASP-2 EDTA and pepstatin
were omitted. Prior to purification the lysate was diluted
to 0.5% (wt/vol) detergent with the above buffer/inhibi-
tor solution. Ni2+ – affinity purification was carried out as
recommended by the manufacturers using a pre-charged
Ni2+ column, 1 ml of settled bed resin for 50  106 cells
with minor alterations; all binding and washes (with in-
creasing imidazole concentrations, pH 7.4) were carried
out in PBS buffer supplemented with 0.2% (wt/vol) NP40
to reduce non-specific binding. Elution was achieved with
300 mM imidazole/0.2% (wt/vol/) detergent.
Protein incubations
Freshly purified ASP-2 was dialysed immediately into 50
mM CH3COONa, 20 mM NaCl, 0.2% (wt/vol) NP-40, at
either pH 8.5 or 5, at 4C overnight, in the presence of 1
M Leupeptin and 1 mM PMSF. The protein solution was
then incubated at room temperature for two hours before
SDS-PAGE, in vitro cleavage reactions, or N-terminal se-
quencing. For Mass Spectrometry the proteins were first
dialysed in the above buffer at pH 8.5, and then the pH
was adjusted with dilute acetic acid to ph 5. For N-termi-
nal peptide sequencing the samples were immobilised on
a PVDF membrane.
Immunoprecipitations and in vitro cleavage assays
Anti-CT15 (2 g/ml) was used to immunoprecipitate
(Stephens and Austen 1996) APPswe from HEK293 cell
lysates/extracts prepared as above. The pellet was resus-
pended in reaction buffer (20 mM CH3COONa, ph 5, 50
mM NaCl, 0.2% NP40, 1 mM PMSF and 1 M Leupeptin)
prior to the addition of ASP-2 (purified and pre-incubated
in reaction buffer at designated pH). Reactions were car-
ried out for 2 hours at 37C. Samples were analysed by
SDS-PAGE on a 16.5% Tris-Tricine gel as described by the
manufacturers followed by western blotting and detection
with anti-CT15 IgG (0.5 g/ml) or 6E10 (4 g/ml).
Mass spectrometry
Purified ASP-2 which had been dialysed at pH 8.5 as de-
scribed above was pre-incubated in the reaction buffer ti-
trated at the designated pH without detergent prior to
absorption to a C-18 ZIP tip (Millipore) equilibrated with
0.1% (vol/vol) trifluorocetic acid, (TFA). Peptides were
eluted with 50% (vol/vol) acetonitrile and analysed on an
Axima-CFR KRATOS Mass Spectrometer after addition of
an equal volume of 10 mg/ml -cyano-4-hydroxycinnam-
ic acid (Sigma) in 50% (vol/vol) acetonitrile. Angiotensin
1, the dimeric form of -cyano-4-hydroxycinnamic acid,
and neuropeptide Y were used as external calibrants spot-
ted on an adjacent spot on the chip.
Peptide synthesis and IgG production
The C-terminal peptide of ASP-2 (CLRQQHDDFADDIS-
LLK residues 482–501) was synthesised on a Milligen
9050 synthesizer using Fmoc N-terminal protection and,
after deprotection and release from resin was purified by
HPLC on a column of Vydac C4 with gradients of ace-
tonitrile in 0.1% TFA. In brief, bovine thyroglobulin was
activated with succinimidyl 4-(N-maleimido-methyl) cy-
clohexane-1-carboxylate, desalted on a Sephadex G-10
column and coupled to the HPLC-purified synthetic pep-
tide utilising its free-cysteine as described in [45]. The cou-
pled peptide was used to immunise rabbits and its
immunoreactivity was screened by ELISA using immobi-
lised antigenic peptide. Reactive serum was purified on a
peptide-conjugated Sepharose column, aliquoted and
stored at -20C. Pure anti-ASP-2 IgG was tested for its spe-
cificity towards ASP-2 by western blotting of extracts of re-
combinant clones as well as mock-transfected cells using
purified IgG pre-incubated or not with excess antigenic
peptide.
Metabolic labelling and detection of recombinant proteins
80% Confluent flasks of HEK293 APPswe-trasfected cells
(~5  106 cells) were depleted of Methionine by incuba-
tion in Met-free media supplemented with FCS and
Glutamax and pyruvate for 1 hr. The same media was then
supplemented with [35S]-Met at 50 Ci/ml in 5 mls, and
incubated for 3 hrs. Cells were first rinsed with PBS and
then lysed and extracted as described earlier. The [35S]-la-
belled protein was immunoprecipitated as described ear-
lier and reactions with ASP-2 were carried out. These were
analysed by 7% SDS-PAGE, soaked in AmplifyTR for 15
minutes and dried before exposure to Kodak X-Omat film.BMC Biochemistry 2002, 3 http://www.biomedcentral.com/1471-2091/3/25
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SDS-PAGE and Immunoblotting
Proteins were first denatured by boiling in SDS sample
buffer (0.25 M Tris-HCl, pH 8.8, 2.2% (wt/vol) SDS, 10%
(v /v) Glycerol, 0.05% (wt/vol) bromophenol blue) with
or without reducing agent (1% -mercaptoethanol and/or
10 mM DTT) and electrophoresed on SDS-PAGE gels pre-
pared as described by the manufacturers of the acrylamide
solution (National Diagnostics) and run using a BioRad
Mini-Gel system at 20 mA per gel. The gels were subse-
quently transferred onto PVDF membrane using a Biorad
semi-dry blotter in 25 mM Tris, 192 mM Glycine, and
20% (vol/vol) methanol. Antibody detection was carried
out by immunoblotting as described in Stephens and
Austen (1996). For silver staining, gels were fixed with
methanol, 40% (vol/vol) and acetic acid 10% (vol/vol),
for one hour, before they were soaked for 30 min in DTT
(0.5 g/ml). The gels were rinsed twice with water and
soaked for one hour in AgNO3, 0.1% (wt/vol) prior to de-
velopment with a solution of Na2CO3, 3% (wt/vol) and
formaldehyde, 0.0185% (vol/vol).
PNGase treatment
Cellular extracts or purified ASP-2 were first heat-dena-
tured in the presence of 0.5% (wt/vol) SDS in PBS, pH8
and the rest of the procedure was carried out as described
by the manufacturers.
Abbreviations
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